Literature DB >> 25899072

Obesity increases the risk of renal involvement in children with Henoch-Schönlein purpura.

Yong-Li Zhao1, Zheng-Juan Liu2, Xue-Mei Bai3, Yu-Chuan Wang4, Guo-Hua Li5, Xue-Yan Yan6.   

Abstract

UNLABELLED: The main aim of this study was to evaluate the relationship between obesity and renal involvement in children with Henoch-Schönlein purpura (HSP). A retrospective study of 141 pediatric patients with HSP was conducted in our hospital. The clinical data of all patients were collected from the electronic medical record management system from January 2010 to June 2014. The possible risk factors of renal involvement, especially obesity, were analyzed using univariate and multivariate analyses. Renal involvement occurred in 45/141 of the patients. A univariate analysis showed that an age more than 7 years at onset, persistent purpura, obesity, time from symptoms onset to diagnosis more than 14 days, and decreased C3 all increased the risk of renal involvement in HSP. The forward stepwise logistic regression analysis indicated obesity (odds ratio (OR) 4.43, 95 % confidence interval (CI) 1.896 to 10.358), age more than 7 years at onset (OR 2.81, 95 % CI 1.142 to 6.907), and persistent purpura (OR 2.57, 95 % CI 1.119 to 5.909) were independent risk factors for renal involvement.
CONCLUSIONS: Our results show that obesity can increase the hazard of renal involvement in children with HSP and reconfirm that older age at onset and persistent purpura are the independent risk factors for renal involvement. WHAT IS KNOWN: • There have been some reports that obesity was associated with the development of renal injury. • It is not clear whether obesity can increase the risk of renal involvement in children with HSP. What is New: • The main finding of this study is that obesity can increase the hazard of renal involvement in children with HSP.

Entities:  

Keywords:  Children; Henoch–Schönlein purpura; Obesity; Renal involvement; Risk factors

Mesh:

Year:  2015        PMID: 25899072     DOI: 10.1007/s00431-015-2547-z

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  35 in total

Review 1.  The diagnosis and classification of Henoch-Schönlein purpura: an updated review.

Authors:  Yao-Hsu Yang; Hsin-Hui Yu; Bor-Luen Chiang
Journal:  Autoimmun Rev       Date:  2014-01-12       Impact factor: 9.754

2.  Clinical outcome in children with Henoch-Schönlein nephritis.

Authors:  Sevgi Mir; Onder Yavascan; Fatma Mutlubas; Betul Yeniay; Ferah Sonmez
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

3.  [Body mass index cut-offs for overweight and obesity in Chinese children and adolescents aged 2 - 18 years].

Authors:  Hui Li; Xin-nan Zong; Cheng-ye Ji; Jie Mi
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2010-06

4.  Elevated plasma advanced oxidation protein products in children with Henoch-Schonlein purpura.

Authors:  Nurcan Keskin; Mahmut Civilibal; Murat Elevli; Macit Koldas; Nilgun Selcuk Duru; Humeyra Ozturk
Journal:  Pediatr Nephrol       Date:  2011-05-08       Impact factor: 3.714

5.  Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children.

Authors:  Outi Jauhola; Jaana Ronkainen; Olli Koskimies; Marja Ala-Houhala; Pekka Arikoski; Tuula Hölttä; Timo Jahnukainen; Jukka Rajantie; Timo Ormälä; Juha Turtinen; Matti Nuutinen
Journal:  Arch Dis Child       Date:  2010-09-18       Impact factor: 3.791

6.  Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study.

Authors:  Wen-Liang Chang; Yao-Hsu Yang; Li-Chieh Wang; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Pediatr Nephrol       Date:  2005-06-10       Impact factor: 3.714

7.  EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.

Authors:  Seza Ozen; Angela Pistorio; Silvia M Iusan; Aysin Bakkaloglu; Troels Herlin; Riva Brik; Antonella Buoncompagni; Calin Lazar; Ilmay Bilge; Yosef Uziel; Donato Rigante; Luca Cantarini; Maria Odete Hilario; Clovis A Silva; Mauricio Alegria; Ximena Norambuena; Alexandre Belot; Yackov Berkun; Amparo Ibanez Estrella; Alma Nunzia Olivieri; Maria Giannina Alpigiani; Ingrida Rumba; Flavio Sztajnbok; Lana Tambic-Bukovac; Luciana Breda; Sulaiman Al-Mayouf; Dimitrina Mihaylova; Vyacheslav Chasnyk; Claudia Sengler; Maria Klein-Gitelman; Djamal Djeddi; Laura Nuno; Chris Pruunsild; Jurgen Brunner; Anuela Kondi; Karaman Pagava; Silvia Pederzoli; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2010-05       Impact factor: 19.103

8.  Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.

Authors:  C-S Kim; H-S Park; T Kawada; J-H Kim; D Lim; N E Hubbard; B-S Kwon; K L Erickson; R Yu
Journal:  Int J Obes (Lond)       Date:  2006-03-14       Impact factor: 5.095

9.  Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura.

Authors:  Donato Rigante; Marcello Candelli; Gilda Federico; Francesco Bartolozzi; Maria Grazia Porri; Achille Stabile
Journal:  Rheumatol Int       Date:  2004-03-06       Impact factor: 2.631

10.  Body mass index in 1.2 million adolescents and risk for end-stage renal disease.

Authors:  Asaf Vivante; Eliezer Golan; Dorit Tzur; Adi Leiba; Amir Tirosh; Karl Skorecki; Ronit Calderon-Margalit
Journal:  Arch Intern Med       Date:  2012-11-26
View more
  8 in total

1.  Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center.

Authors:  Izabel M Buscatti; Beatriz B Casella; Nadia E Aikawa; Andrea Watanabe; Sylvia C L Farhat; Lucia M A Campos; Clovis Artur Silva
Journal:  Clin Rheumatol       Date:  2018-01-13       Impact factor: 2.980

2.  Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis.

Authors:  Han Chan; Yan-Ling Tang; Xiao-Hang Lv; Gao-Fu Zhang; Mo Wang; Hai-Ping Yang; Qiu Li
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

3.  Henoch-Schonlein Purpura in Children Hospitalized at a Tertiary Hospital during 2004-2015 in Korea: Epidemiology and Clinical Management.

Authors:  Yong Hee Lee; Yu Bin Kim; Ja Wook Koo; Ju-Young Chung
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2016-09-29

4.  Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch-Schönlein purpura: A retrospective study.

Authors:  Ke Wang; Xiaomei Sun; Yang Cao; Liang Dai; Feiyang Sun; Ping Yu; Liqun Dong
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  Obesity is associated with Henoch-Schönlein Purpura Nephritis and development of end-stage renal disease in children.

Authors:  Xin Zheng; Qiaobin Chen; Lang Chen
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

Review 6.  New Insights and Challenges Associated With IgA Vasculitis and IgA Vasculitis With Nephritis-Is It Time to Change the Paradigm of the Most Common Systemic Vasculitis in Childhood?

Authors:  Marija Jelusic; Mario Sestan; Teresa Giani; Rolando Cimaz
Journal:  Front Pediatr       Date:  2022-03-15       Impact factor: 3.418

7.  Streptococcal infection in childhood Henoch-Schönlein purpura: a 5-year retrospective study from a single tertiary medical center in China, 2015-2019.

Authors:  Guo Zhen Fan; Rui Xue Li; Qi Jiang; Man Man Niu; Zhen Qiu; Wei Xia Chen; Hui Hui Liu; Jin Wei Ruan; Peng Hu
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-02       Impact factor: 3.054

8.  Gastrointestinal involvement and its association with the risk for nephritis in IgA vasculitis.

Authors:  Mario Sestan; Nastasia Kifer; Marijan Frkovic; Matej Sapina; Sasa Srsen; Mateja Batnozic Varga; Aleksandar Ovuka; Martina Held; Ana Gudelj Gracanin; Ana Kozmar; Stela Bulimbasic; Marijana Coric; Gordana Laskarin; Alenka Gagro; Marija Jelusic
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-30       Impact factor: 5.346

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.